Literature DB >> 9082340

[99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma].

H Elser1, M Henze, C Hermann, W Eckert, U Mende.   

Abstract

AIM: The aim of the study has been the examination of the diagnostic value of 99mTc-MIBI scintigraphy for the detection of local tumor or metastases following total thyroidectomy and 131I ablation therapy in differentiated thyroid carcinoma.
METHODS: MIBI-scintigraphy has been indicated in 85 patients because of ascending thyroglobulin values or suspected local recurrencies by ultrasonography. The results have been compared to cytology or histology or ultrasonography, computed tomography, X-ray and radioiodine scanning.
RESULTS: MIBI scintigraphy was found positive in 32 of 40 metastases. Only 18 metastases have been seen by radioiodine. MIBI scintigraphy was most effective in detecting local tumor recurrencies and lymph node metastases (94%). The specificity of MIBI and radioiodine was similar (100%). In inflammatory enlarged lymph nodes no MIBI uptake was found, so it is possible to differentiate reactive lymph node enlargement from metastatic disease.
CONCLUSION: In conclusion scintigraphy with 99mTc-MIBI is advisable in suspected local recurrencies and negative radioiodine scan. It is favourable that withdrawing TSH-suppressive hormone medication is not necessary.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9082340

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  3 in total

1.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.

Authors:  Di Wu; Dorina Ylli; Cristiane J Gomes Lima; Wen Lee; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

2.  Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation.

Authors:  A Campennì; R M Ruggeri; M Siracusa; S A Pignata; F Di Mauro; A Vento; F Trimarchi; S Baldari
Journal:  J Endocrinol Invest       Date:  2018-03-16       Impact factor: 4.256

3.  Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.

Authors:  Michael E Spieth; Steven B Standiford; Marjorie E Starkman; John Gough
Journal:  Clin Med Res       Date:  2003-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.